Longeveron appoints Stephen Willard as CEO; Powell resigns; 50% salary deferral enacted

Longeveron Inc.

Stephen H. Willard appointed permanent CEO effective Feb 11, 2026; succeeds interim CEO Than Powell who remains in BD role.
Willard receives base salary $500K/yr, deferred to $250K during temporary 50% deferral period for CEO and Executive Chairman.
Initial equity grant: 200K shares, 200K RSUs, 200K stock option; all vest quarterly over four years.
Company implements cost reductions: 50% salary deferral for CEO/Exec Chairman, furloughs, reduced board fees; 50K RSUs to each exec.
Pivotal Phase 2b HLHS trial top-line results expected Q3 2026; FDA guidance that success could support BLA filing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.